Platelet receptor polymorphisms and their role in cardiovascular disease

LaboratoriumsMedizin

Volumn 26, Issue 11-12, 2002, Pages 584-593

  Zotz, R B ^a,b   Scharf, R E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

GPIa IIa; GPIIb IIIa; Myocardial infarction; Platelet membrane glycoproteins; Platelet receptor polymorphisms; Stroke

Indexed keywords

INTEGRIN; RECEPTOR SUBUNIT; THROMBOCYTE RECEPTOR;

ALLELE; ANTIGENICITY; ARTERY DISEASE; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPOTHESIS; PHENOTYPE; PROTEIN POLYMORPHISM; RISK FACTOR; THROMBOCYTE MEMBRANE; THROMBOGENICITY;

EID: 0036868215     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2002.065     Document Type: Article

References (130)

1. DeWood MA, Spores J, Hensley GR, Simpson CS, Eugster GS, Sutherland KI. Coronary arteriographic findings in acute transmural myocardial infarction. Circulation 1983;68(2 Pt 2):139-149.
2. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315 (16):983-9.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326(4):242-250.
4. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994;24(7):1591- 1601.
5. Lam JY, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: Relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986;8(6):1380-6.
6. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000;342(2):101-114.
7. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126.
8. Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 92;3684-3693.
9. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998;94:657-666.
10. Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: A multi functional adhesion receptor. Haematologica 1992;77:162-8.
11. Nurden AT. Polymorphism of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemost 1995;74:345-51.
12. Scharf RE. Molecular basis and clinical aspects of hereditary megakaryocyte and platelet membrane glycoprotein disorders. Haemostaseologie 1996;16:114-38.
13. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
14. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114:835-9.
15. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991;84:708-11.
16. Verheut FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990;66:267-70.
17. The RISC Group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
18. Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia: The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 1992;340:497-501.
19. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340;1421-5.
20. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7:251-69.
21. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-9.
22. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
23. Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989;21:393-405.
24. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
25. Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley D, Worley SJ, Weisman HF, Califf RM, Topol EJ, for the EPIC investigators. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the EPIC trial. J Am Coll Cardiol 1996;28:849-55.
26. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-59.
27. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992;80:1386-1404.
28. von dem Borne AEGK, Ouwehand WH, Kuijpers RWAM. Theoretical and practical aspects of platelet crossmatching. Transfusion Medicine Reviews 1990;4:265-78.
29. Mollison PL, Engelfriet CP, Contreras M. Blood Transfusion in Clinical Medicine. Blackwell Scientific Publications (Oxford) 1993;592-637.
30. Slichter SS. Platelet alloimmunization In: Anderson KC, Ness PM, editors. Scientific Basis of Transfusion Medicine. Philadelphia, W.B. Saunders 1994;527-43.
31. Nurden AT. Polymorphisms of the platelet receptors as risk factors in coronary thrombosis. Eur Heart J. 1996;17:1293-4.
32. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-81.
33. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-4.
34. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385-8.
35. Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, Marz W, Scharf RE. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998;79:731-5.
36. Batalla A, Cubero GI, Reguero JR, Coto E. Platelet Pl(A) polymorphism, myocardial infarction, and extent of coronary artery disease. Circulation 1998;98:826-7.
37. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997;96:1424-31.
38. Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996;335:1071-2.
39. Odawara M, Matsunuma A, Yamashita K. Platelet glycoprotein IIIa PlA polymorphism and Japanese diabetic patients with coronary heart disease. Lancet 1996;348:1310.
40. Carter AM, Mansfield MW, Grant PJ. Polymorphisms of platelet glycoproteins in relation to macrovascular disease in type 2 diabetes mellitus. Diabet Med 1998;15:315-9.
41. A1/A2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998;82:13-6.
42. Abbate R, Marcucci R, Camacho-Vanegas O, Pepe G, Gori AM, Capanni M, Simonetti I, Prisco D, Gensini GF. Role of platelet glycoprotein Pl(A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1998;82:524-5.
43. Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, Maurer G, Mayr WR, Panzer S. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 1998;90:117-23.
44. Garg UC, Arnett DK, Folsom AR, Province MA, Williams RR, Eckfeldt JH. Lack of association between platelet glycoprotein IIb/ IIIa receptor PlA polymorphism and coronary artery disease or carotid intima-media thickness. Thromb Res 1998;89:85-9.
45. Grand'Maison A, Jacques L, Demers C, Marcoux S, Delage R. PECAM-1/CD31 and GPIIb/IIIa polymorphism and their roles in acute coronary thrombosis. Blood 1998;92 (Suppl 1):190a (Abstract).
46. Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz PM, Felix SB, Roots I, Baumann G, Stangl K. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study. Lancet 1999;353:708-12.
47. Batalla A, Reguero JR, Cubero GI, Coto E. Platelet glycoprotein IIIa polymorphisms, plasma lipoprotein(a) concentration and early coronary disease. Atherosclerosis 1999;147:202.
48. Boncler M, Rozalski M, Chizynski K, Watala C. Analysis of platelet glycoprotein polymorphisms in patients with ischemic heart disease - A preliminary study in Polish population. Thromb Haemost 1999;82 (Suppl):377 (Abstract).
49. Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M, Tillmanns H, Hehrlein FW, Rau M, Haberbosch W. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998;80:214-7.
50. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 1999;33:727-33.
51. Bottiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schomig K, von Beckerath N, Schomig A. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000;83:559-62.
52. Garcia-Ribes M, Gonzalez-Lamuno D, Hernandez-Estefania R, Colman T, Pocovi M, Delgado-Rodriguez M, Garcia-Fuentes M, Revuelta JM. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis. Thromb Haemost 1998;79:1126-29.
53. Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lalu K, Penttila A, Karhunen PJ. Glycoprotein IIIa PI(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999;19:2573-78.
54. Cannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald E. PlA2 polymorphism of the platelet IIb/IIIa receptor: Increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: Results from TIMI 12. Circulation 1998;98 (Suppl I):171 (Abstract).
55. Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa PlA polymorphism in young men with myocardial infarction. Lancet 1996;348:485-6.
56. Araujo F, Santos A, Araujo V, Henriques I, Monteiro F, Meireles E, Moreira I, David D, Maciel MJ, Cunha-Ribeiro LM. Genetic risk factors in acute coronary disease. Haemostasis 1999;29:212-8.
57. Merlini PA, Ardissino D, Ferrario M, Fetiveau R, Tubaro M, Galvani M, Ottani F, Tagliabue L, Duca F, Sacchi E, Mannucci PM. Interactions between environmental and prothrombotic genetic risk factors in young survivors of myocardial infarction. Circulation 1998;98(Suppl I):458 (Abstract).
58. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46-51.
59. Pastinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Vartiainen E, Peltonen L, Syvanen A. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet 1998;7:1453-62.
60. A1/A2 in diabetic and non-diabetic patients with acute ischaemic events. Eur Heart J 1998;19(Suppl):107 (Abstract).
61. Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study. Lancet 1999;353:351-4.
62. Casorelli I, De S, V, Leone AM, Chiusolo P, Burzotta F, Paciaroni K, Rossi E, Andreotti F, Leone G, Maseri A. The C807T/ G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001;114:150-4.
63. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98:3256-3260.
64. Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis - Role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinolysis 1997;8:284-90.
65. Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742-7.
66. Aleksic N, Juneja H, Folsom AR, Ahn C, Boerwinkle E, Chambless LE, Wu KK. Platelet Pl(A2) allele and incidence of coronary heart disease: Results from the Atherosclerosis Risk In Communities (ARIC) Study. Circulation 2000;102:1901-5.
67. Senti M, Aubo C, Bosch M, Pavesi M, Pena A, Masia R, Marrugat J. Platelet glycoprotein IIb/IIIa genetic polymorphism is associated with plasma fibrinogen levels in myocardial infarction patients. The REGICOR Investigators. Clin Biochem 1998;31:647- 51.
68. Joven J, Simo JM, Vilella E, Camps J, Masana L, de Febrer G, Camprubi M, Richart C, Bardaji A, Casao E, Pocovi M, Civeira F. Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. Atherosclerosis 1998;140:155-9.
69. Senti M, Aubo C, Bosch M. The relationship between smoking and triglyceride-rich lipoproteins is modulated by genetic variation in the glycoprotein IIIa gene. Metabolism 1998;47:1040-1.
70. Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996;348:1309-10.
71. Chen F, Jian Z, Xie Q, Pu X, Xiao B, Han L. Polymorphism of human platelet alloantigen in Chinese patients with acute myocardial infarction and acute ischemic stroke. Chin Med J 2000;113:702-5.
72. Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 1997;33:693-97.
73. Hato T, Minamoto Y, Fukuyama T, Fujita S. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 1997;80:1222-4.
74. Herrmann SM, Poirier O, Marques-Vidal P, Evans A, Arveiler D, Luc G, Emmerich J, Cambien F. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Temoins de l'Infarctus du Myocarde. Thromb Haemost 1997;77:1179-81.
75. Kettling C, Kastrati A, Koch W, Mehilli J, von Beckerath N, Schomig K, Koetz F, Seidl H, Elezi S, Schomig A. Is PlA polymorphism of platelet glycoprotein IIIa associated with acute myocardial infarction? Eur Heart J 1998;19(Suppl):360 (Abstract).
76. Durante-Mangoni E, Davies GJ, Ahmed N, Ruggiero G, Tuddenham EG. Coronary thrombosis and the platelet glycoprotein IIIA gene PlA2 polymorphism. Thromb Haemost 1998;80:218-9.
77. Scaglione L, Bergerone S, Gaschino G, Imazio M, Maccagnani A, Gambino R, Cassader M, Di Leo M, Macchia G, Brusca A, Pagano G, Cavallo-Perin P. Lack of relationship between the PlA1/ PlA2 polymorphism of platelet glycoprotein IIIa and premature myocardial infarction. Eur J Clin Invest 1998;28:385-8.
78. Cenarro A, Casao E, Civeira F, Jensen HK, Faergeman O, Pocovi M. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous familial hypercholesterolemia. Atherosclerosis 1999;143:99-104.
79. Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK, Whitsett C, Rawlins P, Evatt BL. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999;116:880-6.
80. Kekomaki S, Hamalainen L, Kauppinen-Makelin R, Palomaki H, Kaste M, Kontula K. Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke. J Cardiovasc Risk 1999;6:13-7.
81. Brscic E, Bergerone S, Gagnor A, Colajanni E, Matullo G, Scaglione L, Cassader M, Gaschino G, Di Leo M, Brusca A, Pagano GF, Piazza A, Trevi GP. Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J 2000;139:979-84.
82. Barakat K, Kennon S, Hitman GA, Aganna E, Price CP, Mills PG, Ranjadayalan K, North B, Clarke H, Timmis AD. Interaction between smoking and the glycoprotein IIIa Pl(A2) polymorphism in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2001;38:1639-643.
83. Benze G, Heinrich J, Schulte H, Rust S, Nowak-Gottl U, Tataru MC, Kohler E, Assmann G, Junker R. Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J 2002;23:325-30.
84. Morita H, Kurihara H, Imai Y, Sugiyama T, Hamada C, Sakai E, Mori M, Nagai R. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and myocardial infarction in Japanese. An approach entailing melting curve analysis with specific fluorescent hybridization probes. Thromb Haemost 2001;85:226-30.
85. Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ, Daly ME. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999;106:771-6.
86. Sacchi E, Tagliabue L, Duca F, Landi G, Merlini PA, Mannucci PM. A C807T substitution in the platelet collagen receptor integrin alpha2 beta1 gene is a genetic risk factor for stroke at a young age but not for myocardial infarction. Haematologica 2000;85(Suppl):10-11 (Abstract).
87. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PlA1/PlA2 and coronary risk: A meta-analysis. Thromb Haemost 2001;85:626-33.
88. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000;86:1000-5.
89. Kastrati A, Koch W, Gawaz M, Mehilli J, Bottiger C, Schomig K, von Beckerath N, Schomig A. PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 2000;36:84-9.
90. Zotz RB, Klein M, Dauben HP, Moser C, Gams E, Scharf RE. Prospective analysis after coronary-artery bypass grafting: Platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death. Thromb Haemost 2000;83:404-7.
91. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997;350:1217-9.
92. Walter DH, Schachinger V, Elsner M, Mach S, Dimmeler S, Auch-Schwelk W, Zeiher AM. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene. Eur Heart J 2001;22:587-95.
93. Mehilli J, Kastrati A, Koch W, Gawaz M, Elezi S, Kettling C, Schomig K, von Beckerath N. Patients homozygous for the PlA2 allele coding for platelet glycoprotein IIIa are at increased risk for stent vessel thrombosis. Circulation 1998;98(Suppl I):288 (Abstract).
94. Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottiger C, Mehilli J, Schomig K, von Beckerath N. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-10.
95. Kunicki TJ, Honda S, Dawson B, Honda Y, Ruan C, Aster RH. The PlA alloantigen system is a sensitive indicator of the structural integrity of the amino-terminal domain of the human integrin beta 3 subunit. Blood Cells Mol Dis 1995;21:131-41.
96. Feng D, Lindpaintner K, Larson MG, O'Donnell CJ, Lipinska I, Sutherland PA, Mittleman M, Muller JE, D'Agostino RB, Levy D, Tofler GH. Platelet glycoprotein IIIa Pl(A) polymorphism, fibrinogen, and platelet aggregability: The Framingham Heart Study. Circulation 2001;104:140-44.
97. Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D'Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-47.
98. Ripoll L, Kereveur A, Mazoyer E, Kubis N, Woimant F, Drouet LO. PLA platelet GPIIb/IIIa polymorphism is associated with increased platelet aggregation and risk of ischemic stroke in the young. Circulation 1998;98 (Suppl I):458 (Abstract).
99. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman, L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-18.
100. Theodoropoulos I, Christopoulos C, Metcalfe P, Dimitriadou E, Economopoulos P, Loucopoulos D. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol 2001;114:387-93.
101. Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger JN, Aiach M, Rendu F. Interdonor variability of platelet response to thrombin receptor activation: Influence of PlA2 polymorphism. Br J Haematol 1997;99:801-7.
102. Andrioli G, Minuz P, Solero P, Pincelli S, Ortolani R, Lussignoli S, Bellavite P. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with PI(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000;110:911-8.
103. Goldschmidt-Clermont PJ, Coleman LD, Pham YM, Cooke GE, Shear WS, Weiss EJ, Kral BG, Moy TF, Yook RM, Blumenthal RS, Becker DM, Becker LC, Bray PF. Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease. Arch Pathol Lab Med 1999;123:1223-9.
104. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, Murphy S, FitzGerald GA. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood 2001;97:3093-99.
105. Cadroy Y, Sakariassen K, Grandjean H, Thalamas C, Boneu B, Sie P. The effect of platelet PlA polymorphism on experimental thrombus formation in man depends on blood flow and thrombogenic substrate. Thromb Haemost 2001;85:1097-1103.
106. A2 Blood 1997;90 (Suppl I):256a (Abstract).
107. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000;7:284-9.
108. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000;105:793-802.
109. A polymorphisms on platelets display different sensitivity to angonists and antagonists. Blood 1998;92:28a
110. Cooke GE, Bray PF, Hamlington JD, Pram DM, GoldschmidtClermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet 1998;351:1253.
111. Elices MJ, Hemler ME. The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. Proc Natl Acad Sci USA 1989;86:9906-10.
112. Kirchhofer D, Languino LR, Ruoslahti E, Pierschbacher MD. Alpha 2 beta 1 integrins from different cell types show different binding specificities. J Biol Chem 1990;265:615-8.
113. Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen platelet interactions: Evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 1989;74:182-92.
114. Savage B, Marzec UM, Chao BH, Harker LA, Maraganore JM, Ruggeri ZM: Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein Iib-IIIa complex inhibits receptor function. J Biol Chem 1990;265:11 766-72.
115. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998;92:2382-88.
116. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood 1993;82:2693-2703
117. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997;89:1939-43.
118. Hessner MJ, Dinauer DM, Kwiatkowski R, Neri B, Raife TJ. Age-dependent prevalence of vascular disease-associated polymorphisms among 2689 volunteer blood donors. Clin Chem 2001;47:1879-84.
119. Dinauer DM, Friedman KD, Hessner MJ. Allelic distribution of the glycoprotein Ia (alpha2-integrin) C807T/G873A dimorphisms among caucasian venous thrombosis patients and six racial groups. Br J Haematol 1999;107:563-5.
120. Komurcu E, Erginel-Unaltuna N. Platelet glycoprotein Ia 807C/T (Phe224) and 873 G/A (Thr246) dimorphisms in Turkey. Am J Hematol 2002;69:83-4.
121. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999;93:2449-53.
122. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integarin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999;93:3583-6.
123. Roest M, Banga JD, Grobbee DE, de Groot PG, Sixma JJ, Tempelman MJ, van der Schouw YT. Homozygosity for 807 T polymorphism in alpha2 subunit of platelet alpha2beta1 is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000;102:1645-50.
124. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function - Effect in thromboembolic diseases. Thromb Haemost 1999;81:951-6.
125. Anvari A, Janisiw M, Turel Z, Huber K, Fischer G, Panzer S. Platelet glycoprotein Ia gene dimorphism alpha2-807 in malignant arrhythmia in coronary artery disease. Thromb Res 2000;98:281-6.
126. 1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999;93:3578-82.
127. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-32.
128. Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002;22:14-20.
129. Corral J, Rivera J, Gonzalez-Conejero R, Vicente V. The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. Transfusion 1999;39:372-378.
130. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, Daly ME. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 2001;104:1459-1463.